Quest Partners LLC acquired a new stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities ...

Phathom Pharmaceuticals (PHAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Phathom Pharmaceuticals, Inc. (PHAT) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

Founded in 1935 by Khwaja Abdul Ahmeid, Cipla operates through two segments: Pharmaceuticals and New Ventures. Cipla Limited specialises in developing medications, primarily treating respiratory ...

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its ...

Phathom Pharmaceuticals(PHAT.US)位列第四，持仓约350万股，持仓市值约6319万美元。占投资组合比例为5.63%，较上季度持仓数量无变化。 Q32 Bio(QTTB.US)位列第五，持仓约110万股，持仓市值约4862万美元，占投资组合比例为4.33%，较上季度持仓数量无变化。 第三季度，凯雷 ...

On Friday, Phathom Pharmaceuticals Inc (PHAT) stock saw a decline, ending the day at $8.78 which represents a decrease of $-0.31 or -3.41% from the prior close of $9.09. The stock opened at $9.13 and ...